JO
ACRV icon

John Overdeck’s Acrivon Therapeutics ACRV Stock Holding History

John Overdeck’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.14M Buy
641,498
+252,103
+65% +$428K ﹤0.01% 3508
2026
Q1 		$541K Sell
389,395
-195,674
-33% -$341K ﹤0.01% 3690
2025
Q4 		$1.41M Buy
585,069
+265,864
+83% +$578K ﹤0.01% 2701
2025
Q3 		$578K Buy
319,205
+138,033
+76% +$194K ﹤0.01% 2918
2025
Q2 		$216K Buy
+181,172
New +$249K ﹤0.01% 2892
2023
Q1 		– Sell
-21,534
Closed -$248K – 2923
2022
Q4 		$248K Buy
+21,534
New +$273K ﹤0.01% 2318

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

John Overdeck's ACRV Position: Q2 2026 in Review

John Overdeck increased its Acrivon Therapeutics (ACRV) stake by 65% in Q2 2026, buying an estimated $428K and bringing the position to 641,498 shares worth $1.14M. The position accounts for ﹤0.01% of the portfolio, ranked #3508.

John Overdeck first reported a position in ACRV in Q4 2022 and has held it in 6 quarters since. The position peaked at $1.41M in Q4 2025. 46 funds tracked by Wall St. Rank hold ACRV as of Q2 2026.

  • John Overdeck held 641,498 shares of Acrivon Therapeutics worth $1.14M as of Q2 2026.
  • John Overdeck bought 252,103 Acrivon Therapeutics shares in Q2 2026, an estimated $428K.
  • Acrivon Therapeutics made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #3508 holding.
  • John Overdeck first reported a position in Acrivon Therapeutics in Q4 2022 and has held it in 6 quarters since.
  • John Overdeck's Acrivon Therapeutics position peaked at $1.41M in Q4 2025.
  • 46 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.